Pathophysiology of nonalcoholic steatohepatitis

Journal of Clinical Gastroenterology

Volumn 40, Issue SUPPL. 1, 2006, Pages

  McCullough, Arthur J ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Insulin resistance; Lipid peroxidation; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Indexed keywords

ADIPONECTIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSINOGEN; ANTIBIOTIC AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; BETAINE; CLOFIBRATE; CYTOKINE; CYTOKINE ANTIBODY; FAT; FATTY ACID; GEMFIBROZIL; GLITAZONE DERIVATIVE; GLUCOSE; INSULIN; IRON; LEPTIN; METFORMIN; PROBIOTIC AGENT; PROBUCOL; RESISTIN; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ADIPOCYTE; BACTERIAL INFECTION; BACTERIAL OVERGROWTH; BARIATRIC SURGERY; BLOOD ANALYSIS; BODY FAT DISTRIBUTION; CAUSE OF DEATH; CELL PROTECTION; CONFERENCE PAPER; DIET; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME INHIBITION; EPIDEMIC; EXERCISE; FATTY ACID METABOLISM; FATTY LIVER; GENETIC ANALYSIS; GENOTYPE ENVIRONMENT INTERACTION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUTATHIONE DEFICIENCY; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOPATHOLOGY; INSULIN METABOLISM; INSULIN RESISTANCE; LIFESTYLE; LIPID PEROXIDATION; LIPOLYSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METABOLISM; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHLEBOTOMY; PREVALENCE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RECURRENT DISEASE; UNITED STATES; VASCULAR RESISTANCE; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION;

ANIMALS; ANTIOXIDANTS; DISEASE PROGRESSION; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIFE STYLE; LIPID PEROXIDATION; LIVER CIRRHOSIS; OBESITY; OXIDATIVE STRESS;

EID: 33748150370     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000168645.86658.22     Document Type: Conference Paper

References (229)

1. McCullough AJ. The epidemiology and risk factors of NASH. In: Farrell GC, George J, Hall P, et al, eds. Fatty Liver Disease: NASH and Related Disorders. Oxford: Blackwell, 2005:23-37.
2. Ludwig J, Viggiano T, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hither to un-named disease. Mayo Clin Proc. 1980;55:434-438.
3. Falck-Ytter Y, Younossi ZM, Marchesini G, et al. Clinical features and natural history of nonalcoholic steatosis syndrome. Semin Liver Dis. 2001;21:17-26.
4. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-1395.
5. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413-1419.
6. Bacon BR, Farahvash MJ, Janney CG, et al. Non-alcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107:1103-1109.
7. Powell EE, Cooksley WGE, Hanson RR, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74-80.
8. Lee RG. Non-alcoholic steatohepatitis: a study of 49 patients. Hum Pathol. 1989;20:594-598.
9. Hui JM, Kench JG, Chitturi S, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology. 2003;38:420-427.
10. Rratziu V, Bonyhay L, DiMartino V, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 2002;35:1485-1493.
11. Caldwell SH, Oelgner DH, Jezzoni JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;32:689-692.
12. Caldwell SH, Hespenheide EE. Subacute liver failure in obese women. Am J Gastroenterol. 2002;97:2058-2067.
13. Bugianesi E, Leone A, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular cancer. Gastroenterology. 2002;123:134-140.
14. Ong J, Younossi ZM, Reddy V, et al. Cryptogenic cirrhosis and post-transplantation nonalcoholic fatty liver disease. Liver Transpl. 2001;7:707-801.
15. Teli MR, James OFW, Burt AD, et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22:1714-1719.
16. Dam-Larsen S, Franzmann M, Anderson IB, et al. Long term prognosis of fatty liver disease and death. Gut. 2004;53:750-755.
17. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults 1999-2000. JAMA. 2002;288:1723-1727.
18. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195-1200.
19. Shuldiner AR, Yang R, Gong DW. Resistin, obesity and insulin resistance: the emerging role of the adipocyte as an endocrine organ. N Engl J Med. 2001;345:1345-1346.
20. Yanovski S, Yanovsky JA. Obesity. N Engl J Med. 2002;347:591-602.
21. Strauss RS, Pollock HA. Epidemic increase in childhood overweight, 1986-1998. JAMA. 2001;286:2845-2848.
22. Hill JO, Wyatt HR, Reed GW, et al. Obesity and the environment: where do we go from here? Science. 2003;299:853-855.
23. Blair SN, Nichman MZ. The public health problem of increasing prevalence rates of obesity and what should be done about it. Mayo Clin Proc. 2002;77:109-113.
24. Kimm SYS, Glynn NW, Kriska AM, et al. Decline in physical activity in black and white girls during adolescence. N Engl J Med. 2002;347:709-715.
25. Kyle UG, Morabia A, Schultz Y, et al. Sedentarism affects body fat mass index and fat free mass index in adults aged 18-98 years. Nutrition. 2004;20:255-260.
26. VanDamm RM, Rimm EB, Willett WC, et al. Dietary patterns and risk for type 2 diabetes mellitus in US men. Ann Intern Med. 2002;136:201-209.
27. Seidell JC. Obesity, insulin resistance and diabetes: a world wide epidemic. Br J Nutr. 2000;83(suppl):55-58.
28. Kalhan R, Pathawala K, Agarwal S, et al. Altered lipid profile, leptin, insulin and anthropometry in offspring of South Asian immigrants. Metabolism. 2001;50:1197-1202.
29. Weiss KM, Ferrell RE, Hanis CL. A new world syndrome of metabolic diseases with a genetic and evolutionary basis. Yearb Phys Anthropol. 1984;27:153-178.
30. Musso G, Gambino R, DeMichieli F, et al. Dietary habits and their relation to insulin resistance and post-prandial lipemia in nonalcoholic steatohepatitis. Hepatology. 2003;37:904-916.
31. Solga S, Alkhuraishe AR, Clark JM, et al. Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci. 2004;49:1578-1583.
32. Palmer MA, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology. 1990;99:1408-1413.
33. Ueno T, Sugawara H, Sujaku K. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997;27:103-107.
34. Park HS, Kim MW, Shin ES. Effects of weight control on hepatic abnormalities in obese patients with fatty liver. J Korean Med Sci. 1995;10:414-421.
35. Dixon JB, Bhathal PS, Hughs NR, et al. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology. 2004;39:1647-1654.
36. Wang RJ, Koretz RL, Yee HF. Is weight reduction an effective therapy for nonalcoholic fatty liver? A systemic review. Am J Med. 2003;115:554-559.
37. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106:473-481.
38. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab. 2000;11:327-332.
39. Morrison RF, Farmer SR. Insights into the transcriptional control of adipocyte differentiation. J Cell Biochem Suppl. 1999;32:59-67.
40. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med. 2003;43:1467-1476.
41. Li Z, Diehl AM. Cytokines and inflammatory recruitment in NASH: experimental and human studies. In: Farrell GC, George J, Hall P, et al, eds. Fatty Liver Disease: NASH and Related Disorders. Oxford: Blackwell, 2005:123-131.
42. Uygun A, Kadayifci A, Yesilova Z, et al. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2000;95:3584-3589.
43. LeClercq IA, Farrell GC, Schriemer R, et al. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol. 2002;37:206-213.
44. Chalasani N, Crabb DW, Cummings OW, et al. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol. 2003;98:2771-2776.
45. Rangala SM, Rich AS, Rhoades B, et al. Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes. 2004;53:1937-1941.
46. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307-312.
47. Banerjee RR, Rangwala SM, Shapiro JS, et al. Regulation of fasted blood glucose by resistin. Science. 2004;303:1195-1198.
48. McTerman CL, McTerman PG, Harte AL, et al. Resistin, central obesity and type 2 diabetes. Lancet. 2002;359:46-47.
49. Aihand G, Teboul M, Massiera F. Angiotensinogen, adipocyte differentiation and fatty mass enlargement. Curr Opin Clin Nutr Metab Care. 2002;5:385-389.
50. Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of angiotensinogen II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004;40:1222-1225.
51. Lin HZ, Yang SQ, Chuckaree C, et al. Metformin reverses fatty liver disease in obese, leptin deficient mice. Nat Med. 2000;6:998-1003.
52. Uysal KT, Wiesbrock SM, Marino MW, et al. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature. 1997;389:610-614.
53. Yamakawa T, Tanaka SI, Yamakawa Y, et al. Augmented production of tumor necrosis factor-α in obese mice. Clin Immunol Immunopathol. 1995;75:51-56.
54. Boden G, Cheung P, Stein TP, et al. FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. Am J Physiol Endocrinol Metab. 2002;283:E12-E19.
55. Bergman RN, Ader M. Free fatty acids and the pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab. 2000;11:351-354.
56. Berg AH, Combs TP, Du X, et al. The adipocyte secreted protein ACRP 30 enhances hepatic insulin action. Nat Med. 2001;7:947-953.
57. Pajvani UB, Scherer PE. Adiponectin: systemic contributor to insulin sensitivity. Curr Diabetes Rep. 2003;3:207-213.
58. Spranger J, Kruke A, Mohlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003;361:226-228.
59. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941-946.
60. Tomas E, Tsao TS, Saha AK, et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA. 2002;99:16300-16313.
61. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288-1295.
62. Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112:91-100.
63. Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASSH: TNF-α or adiponectin? Hepatology. 2004;40:46-54.
64. Soodini GR, Hamdy O. Adiponectin and leptin in relation to insulin sensitivity. Metab Syn Rel Dis. 2004;2:114-123.
65. Wei YH, Jun L, Qiang CJ. Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats. Dig Dis Sci. 2004;49:1589-1594.
66. Crespo J, Cayon A, Fernandez-Gil P, et al. Gene expression of tumor necrosis factor alpha and TNF receptors, p55 and p75 in nonalcoholic steatohepatitis patients. Hepatology. 2001;34:1158-1163.
67. Katsuki A, Sumida Y, Murashima S, et al. Serum levels of tumor necrosis factor-α are increased in obese patients with non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab. 1998;83:859-862.
68. Satapathy SK, Garg S, Chauhan R, et al. Beneficial effects of tumor necrosis factor-α inhibition by pentoxifylline on clinical, biochemical and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2004;99:1946-1952.
69. Ueki K, Kondo T, Tseng YH, et al. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance and the metabolic syndrome of the mouse. Proc Natl Acad Sci USA. 2004;101:10422-10427.
70. Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol. 2004;24:5434-5446.
71. Hotamisligil GS, Peraldi A, Budavari A, et al. IRS-1 mediated kinase activity in TNF-α and obesity induced insulin resistance. Science. 1996;272:665-668.
72. Shepherd PR, Kahn SK. Glucose transporters and insulin action. N Engl J Med. 1999;341:248-257.
73. Tafani M, Schneider TG, Pastorino JG, et al. Cytochrome dependent activation of caspase 3 by tumor necrosis factor requires induction of the mitochondrial permeability transition. Am J Pathol. 2000;156:2111-2121.
74. Pastorini JG, Simbula G, Yamamoto K, et al. Cytotoxicity of TNF depends on induction of the mitochondrial permeability transition. J Biochem. 1996;271:29792-29798.
75. Li L, Thomas RM, Suzuki H, et al. A small molecule Smac mimic potentiates trail and TNFa-mediated cell death. Science. 2004;305:1471-1474.
76. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and FAS expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003;125:437-443.
77. Memon RA, Feingold KR. Upregulation of uncoupling protein 2 mRNA in genetic obesity, increased tissue lipid content and TNF-α. Biochim Byophys Acta. 2000;1484:41-50.
78. Memon R, Grunfeld C, Feingold KR. TNF-α is not the cause of fatty liver disease in obese diabetic mice. Nat Med. 2001;7:2-3.
79. Combs TP, Berg AH, Obici S, et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest. 2001;108:1875-1881.
80. Kaser S, Moschen A, Cayon A, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut. 2005;54:117-121.
81. Kamada Y, Tamura S, Kiso S, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology. 2003;125:1796-1807.
82. Arner P. Not all fat is alike. Lancet. 1998;1301-1302.
83. Basu RR, Singh RJ, Basu A, et al. Splanchnic cortisol production occurs in humans: evidence for conversion of cortisone to cortisol via the 11-B hydroxysteroid dehydrogenase (11-B-HSD) type 1 pathway. Diabetes. 2004;53:2051-2059.
84. Gavrila A, Chan JL, Yiannakouris N, et al. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab. 2003;88:4823-4831.
85. Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes. 2004;53(suppl 1):143-151.
86. Basu A, Basu R, Shah P, et al. Systemic and regional free fatty acid metabolism in type 2 diabetes. Am J Physiol Metab. 2001;280:E1000-E1006.
87. Nguyen-Duy TB, Nichaman MZ, Church TS, et al. Visceral fat and liver fat are independent predictors of metabolic risk factors in men. Am J Physiol Endocrinol Metab. 2003;284:E1065-E1071.
88. Carr DB, Utzschneider KM, Hull RL, et al. Intraabdominal fat is a major determinant of the national cholesterol education program adult treatment panel III criteria for the metabolic syndrome. Diabetes. 2004;53:2087-2094.
89. Kral JG, Schaffner F, Pierson RRN, et al. Body fat topography as an independent predictor of fatty liver. Metabolism. 1993;42:548-551.
90. Stranges S, Dorn JM, Muti P, et al. Body fat distribution, relative weight, and liver enzyme levels: a population-based study. Hepatology. 2004;39:754-763.
91. Barzilai N, She L, Liu BQ, et al. Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes. 1999;48:94-98.
92. Marchesini G, Brizi M, Labate AMM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450-455.
93. St-Onge MP, Janssen I, Heymsfield SB. Metabolic synbdrme in normal weight Americans. Diabetes Care. 2004;27:2222-2228.
94. Marchesini G, Forlani G. NASH: From liver disease to metabolic disorders and back to clinical hepatology. Hepatology. 2002;497-499.
95. 2) Asian Indians with normal waist circumference have high cardiovascular risk. Nutrition. 2003;19:503-509.
96. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844-1850.
97. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120:1183-1192.
98. Marchesini G, Bugianesi E. NASH as part of the metabolic (insulin resistance) syndrome. In: Farrell GC, George J, Hall P, et al, eds. Fatty Liver Disease: NASH and Related Disorders. Oxford: Blackwell, 2005:55-65.
99. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
100. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis and the metabolic syndrome. Hepatology. 2003;37:917-923.
101. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999;84: 1513-1517.
102. Chitturi S, Abeygunaseka S, Farrell G, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373-379.
103. Chalasani N, Deeg MA, Persohn S, et al. Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98:1849-1855.
104. Pagano G, Pacini G, Musso G, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology. 2002;35:367-372.
105. Willner IP, Waters B, Patil SR, et al. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency and severity of disease. Am J Gastroenterol. 2001;96:2957-2961.
106. Petersen KF, Befroy D, DuFour S, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science. 2003;300:1140-1142.
107. Iossa S, Mollica MP, Lionetti L, et al. A possible link between skeletal muscle mitochondrial efficacy and age induced insulin resistance. Diabetes. 2004;53:2861-2866.
108. Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and liipid metabolism. Nature. 2001;414:799-806.
109. Samuel VT, Shulman GI. Insulin resistance in NAFLD: potential mechanisms and therapies. In: Farrell GC, George J, Hall P, et al, eds. Fatty Liver Disease: NASH and Related Disorders. Oxford: Blackwell, 2005:38-54.
110. Virkamaki A, Ueki K, Kahn CR. Protein-interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest. 1999;103:931-943.
111. Combettes-Souverain M, Issad T. Molecular basis on insulin action. Diabetes Metab. 1998;24:477-489.
112. Synkiotis GP, Papavassiliou AAG. Serine phosphorylation of insulin receptor substrates-1: a novel target for the reversal of insulin resistance. Mol Endocrinol. 2001;15:1864-1869.
113. Kido Y, Burks DJ, Withers D, et al. Tissue specific resistance in mice with mutations in insulin receptor: IRS-1 and IRS-2. J Clin Invest. 2000;105:199-205.
114. Previs SF, Withers DJ, Ren JM, et al. Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism. J Biol Chem. 2000;275:38990-38994.
115. Das UN. Is obesity an inflammatory condition? Nutrition. 2001;17:953-966.
116. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004;39:188-196.
117. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 2003;38:1008-1017.
118. Sekiya M, Yahagi N, Matsuzaka T, et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology. 2003;38:1529-1539.
119. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity and diet induced insulin resistance with salicylates on targeted disruption of IKKB. Science. 2001;293:1673-1677.
120. Wiggs AJ, Roberts-Thomson JC, McCarthy PJ, et al. The role of small intestinal overgrowth, intestinal permeability, endotoxemia, and tumor necrosis factor-α in the pathogenesis of nonalcoholic steatohepatitis. Gut. 2001;48:206-211.
121. Nazim M, Stamp G, Hodgson HJ. Nonalcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth. Hepatogastroenterology. 1989;36:349-351.
122. Riordan SM, Duncombe VM, Thomas MC, et al. Small intestinal bacterial overgrowth, intestinal permeability, and non-alcoholic steatohepatitis. Gut. 2002;50:136-138.
123. Solga SF, Diehl AM. Nonalcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol. 2003;38:681-687.
124. Neyrinck AM, Taper HS, Gevers V, et al. Inhibition of Kupffer cell activity induces hepatic triglyceride synthesis in fasted rats, independent of lipopolysaccharide challenge. J Hepatol. 2002;36:466-473.
125. Yang SQ, Lin HZ, Lane MD, et al. Obesity increased sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA. 1997;94:2557-2562.
126. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003;37:343-350.
127. Diraison F, Moulin P, Beylot M. Contribution of hepatic de novo lipogenesis and re-esterification of plasma nonesterified fatty acids to plasma triglyceride synthesis during nonalcoholic fatty liver disease. Diabetes Metab. 2003;29:478-485.
128. Charlton M, Sreekumar R, Rasmussen D, et al. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology. 2002;35:898-904.
129. 13C- octanoate breath test. Am J Gastroenterol. 2003;98:2335-2336.
130. Kim JK, Fillmore JJ, Chen Y, et al. Tissue specific overexpression of lipoprotein lipase causes tissue specific insulin resistance. Proc Natl Acad Sci USA. 2001;98:7522-7527.
131. Kim SP, Ellmerer M, VanCritters GW, et al. Primary of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric moderate fat diet in the dog. Diabetes. 2003;52:2453-2460.
132. Tikkainen M, Hakkinen AM, Korsheninn KE, et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes. 2004;53:2169-2176.
133. Day CP, James UF. Steatohepatitis: a tale of two 'hits?' Gastroenterology. 1998;114:842-845.
134. Washington K, Wright K, Shyr Y, et al. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver. Hum Pathol. 2000;31:822-828.
135. Yang S, Zhu H, Li Y, et al. Mitochondrial adaptation to obesity-related oxidant stress. Arch Biochem Biophys. 2000;378:259-268.
136. Chavin KD, Yang S, Lin HZ, et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem. 1999;2784:5692-5700.
137. Cortez-Pinto H, Chatham J, Chacko VP, et al. Alterations in liver ATP homeostasis in human non-alcoholic steatohepatitis: a pilot study. JAMA. 1999;282:1659-1664.
138. Caldwell SH, Chang CY, Nakamoto RK, et al. Mitochondria in nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:595-617.
139. Day CP, James OF. Hepatic steatosis: innocent bystander or guilty party? Hepatology. 1999;27:1463-1466.
140. Yang SQ, Lin HZ, Lane MD, et al. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA. 1997;94:2557-2562.
141. Dong W, Simeonova PP, Gallucci R, et al. Cytokine expression in hepatocytes: role of oxidative stress. J Interferon Cytokine Res. 1999;18:629-638.
142. Chitturi S, Farrell GC. Etiopathogenesis of non-alcoholic steatohepatitis. Semin Liver Dis. 2001;21:27-41.
143. Pessayre D, Beerson A, Fromenty B, et al. Mitochondria in steatohepatitis. Semin Liver Dis. 2001;21:57-69.
144. Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol. 2002;16:663-678.
145. Letteron P, Fromenty B, Terris B, et al. Acute and chronic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol. 1996;24:200-208.
146. MacDonald GA, Bridle KR, Ward PJ, et al. Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominately in acinar zone 3. J Gastroenterol Hepatol. 2001;8:953-958.
147. Mazzanti R, Moscarella S, Bensi G, et al. Hepatic lipid peroxidation and aldehyde dehydrogenase activity in alcoholic and nonalcoholic liver disease. Alcohol Alcohol. 1989;24:121-128.
148. Garcia-Monzon C, Martin Perez E, Lojacono O, et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol. 2000;33:716-724.
149. Sumida Y, Nakashima T, Yoh T, et al. Serum thioredoxin levels is a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J Hepatol. 2003;38:32-38.
150. Seki S, Kitada T, Yamada T, et al. In situ detection of lipid peroxidation and oxidative DNA damage in nonalcoholic fatty liver disease. J Hepatol. 2002;37:56-62.
151. Koruk M, Taysi S, Savas MC, et al. Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. Ann Clin Lab Sci. 2004;34:57-67.
152. Parola M, Pinzani M, Casini A, et al. Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen alpha 1 (I) gene expression in human liver fat-storing cells. Biochem Biophys Res Commun. 1993;194:1044-1050.
153. Lee KS, Buck M, Houglum K, et al. Activation of hepatic stellate cells by TGF alpha and collagen Type J is mediated by oxidative stress through cmyb expression. J Clin Invest. 1995;96:2461-2468.
154. Bedossa P, Houglum K, Trautwein C, et al. Stimulation of collagen alpha 1 (I) gene expression is associated with lipid peroxidation in hepatocellular injury: a link to tissue fibrosis? Hepatology. 1994;19:1262-1271.
155. Harrison SA, Torgerson S, Hayashi P, et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98:2485-2490.
156. Adams LA, Angulo P. Vitamins E and C for the treatment of NASH: duplication of results but lack of demonstration of efficacy. Am J Gastroenterol. 2003;98:2485-2490.
157. Mustata GT, Rosca M, Biemel KM, et al. Paradoxical effects of green tea (camellia sinensis) and antioxidant vitamins in diabetic rats: improved retinopathy and renal mitochondrial defects but deterioration of collagen matrix glycoxidation and cross-linking. Diabetes. 2005;54:517-526.
158. Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37-46.
159. Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol. 2001;35:297-306.
160. Goldstein BJ, Kalyankar M, Wu X. Insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets. Diabetes. 2005;54:311-321.
161. Wanless JR, Bargman JM, Oreopoullos DG, et al. Subcapsular steatonecrosis in response to peritoneal insulin deliver: a clue to the pathogenesis of steatonecrosis in obesity. Mod Pathol. 1989;2:69-74.
162. Khalili K, Lan FP, Hanbidge AE, et al. Hepatic subcapsular steatosis in response to intraperitoneal insulin delivery: CT findings and prevalence. AJR Am J Roentgenol. 2003;180:1601-1604.
163. Li XL, Man K, Ng KT, et al. Insulin in UW solution exacerbates hepatic ischemia/reperfusion injury by energy depletion through the IRS-2/SREBP-1c pathway. Liver Transpl. 2004;10:1172-1182.
164. Paradis V, Perle G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001;74:738-744.
165. Younossi ZM, Gramlich T, Matteoni CA, et al. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004;2:262-265.
166. El-Serag HR, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126:460-468.
167. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004;306:457-461.
168. Muoio DM. Insulin resistance takes a trip through the ER. Science. 2004;306:4285-4426.
169. George DK, Goldwurm S, MacDonald G, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology. 1998;114:311-318.
170. Bonkovsky HL, Jawaid Q, Tortorelli K, et al. Nonalcoholic steatohepatitis and iron increased prevalence of mutations of the HFE gene in nonalcoholic steatohepatitis. J Hepatol. 1999;31:421-429.
171. Bacon BR, Farahvash MJ, Janney CG, et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107:1103-1109.
172. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356-1362.
173. Younossi ZM, Gramlich T, Bacon BR, et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology. 1999;30:847-850.
174. Chitturi S, Weltman M, Farrell GC, et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology. 2002;36:142-149.
175. Bugianesi E, Manzini P, D'Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology. 2004;39:179-187.
176. Fargion S, Mattioli M, Fracanzani AL, et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol. 2001;96:2448-2455.
177. Fernandez Real JM, Casamitjana-Abella R, Ricart-Engel W, et al. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care. 1998;21:62-68.
178. Mendler MH, Turlin B, Moirand R, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology. 1999;117:1155-1163.
179. MacDonald GA, Powell LW. More clues to the relationship between hepatic iron and steatohepatitis: an association with insulin resistance? Gastroenterology. 1999;117:1241-1244.
180. Dinneen SF, Silverberg JD, Batts K, et al. Liver iron stores in patients with non-insulin dependent diabetes mellitus. Mayo Clin Proc. 1994;69:13-15.
181. Riquelme A, Soza A, Nazal L, et al. Histological resolution of steatohepatitis after iron depletion. Dig Dis Sci. 2004;49:1012-1015.
182. Fernandez-Real JM, Penarroja G, Castro A, et al. Blood letting in high-ferritin type 2 diabetes: effects on vascular reactivity. Diabetes Care. 2002;25:2249-2255.
183. Eaton JW, Qian M. Molecular bases of cellular iron toxicity. Free Radic Biol Med. 2002;32:833-840.
184. LeMasters JJ. Rusty notions of cell injury. J Hepatol. 2004;40:696-698.
185. Rauen U, Petrat F, Sustmann R, et al. Iron induced mitochondrial permeability transition in cultured hepatocytes. J Hepatol. 2004;40:607-615.
186. Bulteau AL, O'Neill HA, Kennedy MC, et al. Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science. 2004;305:242-245.
187. Lieber CS. CYP2E1 from ASH to NASH. Hepatol Res. 2004;28:1-11.
188. Leclerq IA, Farrell GC, Field J, et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest. 2000;105:1067-1075.
189. George J, Pera N, Phung N, et al. Lipid peroxidation stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol. 2003;39:756-764.
190. Videla LA, Rodrigo R, Orelland M, et al. Oxidation stress-related parameters in the liver of nonalcoholic fatty liver disease patients. Clin Sci. 2004;106:261-268.
191. Koruk M, Taysi S, Savas MC, et al. Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. Ann Clin Lab Sci. 2004;34:57-62.
192. Loguercio C, De Girolamo V, de Sio I, et al. Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. J Hepatol. 2001;35:568-574.
193. Nehra V, Angulo P, Buchman AL, et al. Nutritional and metabolic considerations in the etiology of non-alcoholic steatohepatitis. Dig Dis Sci. 2001;46:2347-2352.
194. Mavretis PG, Ammon HV, Gleysteen JJ, et al. Hepatic free fatty acids in alcoholic liver disease and obesity. Hepatology. 1983;3:226-231.
195. Clarke SD. Nonalcoholic steatosis and steatohepatitis: I. Molecular mechanism for polyunsaturated fatty acid regulation of gene transcription. Am J Physiol Gastrointest Liver Physiol. 2001;281:G865-G869.
196. Rao MS, Reddy JK. Peroxisomal beta-oxidation and steatohepatitis. Semin Liver Dis. 2001;21:1067-1075.
197. Yang S, Zhu H, Li Y, et al. Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys. 2000;378:259-268.
198. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology. 1996;116:1645-1653.
199. Weltman MD, Farrell GC, Hall P, et al. Hepatic cytochrome P4502E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology. 1998;27:128-133.
200. Chalasani N, Gorski C, Asghar MS, et al. Hepatic cytochrome P4502E1 activity in non-diabetic patients with nonalcoholic steatohepatitis. Hepatology. 2003;37:544-550.
201. De la Maza MP, Hirsch S, Petermann M, et al. Changes in microsomal activity in alcoholism and obesity. Alcoh Clin Exp Res. 2000;24:605-610.
202. Emery MG, Fisher JM, Chien JY, et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology. 2003;38:428-435.
203. Ip E, Farrell GC, Hall P, et al. Administration of the potent PPAR alpha agonist, Wyeth 14,643 reverses nutritional fibrosis and steatohepatitis in mice. Hepatology. 2004;39:1286-1296.
204. Araya J, Rodrigo R, Videla LA, et al. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci. 2004;106:635-643.
205. Caldwell SH, Swerdlow RH, Khan EM, et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol. 1999;31:430-440.
206. Perez-Carreras M, Hoyo PD, Martin MA, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology. 2003;38:999-1007.
207. Nair S, Chacko VP, Arnold C, et al. Hepatic ATP reserve and efficiency of replenishing comparison between obese and non-obese normal individuals. Am J Gastroenterol. 2003;98:466-470.
208. Caraceni P, Bionchi C, Domenicali M, et al. Impairment of mitochondrial oxidative phosphorylation in rat fatty liver exposed to preservation reperfusion injury. J Hepatol. 2004;41:82-88.
209. Dianzani MU, Scuro S. The effects of some inhibitors of oxidative phosphorylation on the morphology and enzymatic activities of mitochondria. Biochem J. 1956;61:205-215.
210. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol. 2004;2:1048-1058.
211. Al-osaimi A, Berg C. Intermittent disconjugate gaze: a novel finding in nonalcoholic steatohepatitis and cryptogenic cirrhosis [Letter]. Hepatology. 2005;41:943.
212. Lanquin D. Diabetic insulin secretion and the pancreatic beta cell mitochondrion. N Engl J Med. 2001;345:1772-1774.
213. Poli G. Pathogenesis of liver fibrosis: the role of oxidative stress. Mol Aspects Med. 2000;21:49-98.
214. Rashid A, Wu TC, Huang GC, et al. Mitochondrial protein that regulate apoptosis and necrosis are induced in mouse fatty liver. Hepatology. 1999;29:1131-1138.
215. Ribeiro PS, Cortez-Pinto H, Sola S, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol. 2004;99:1708-1717.
216. Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology. 2004;39:273-278.
217. Li Z, Oben JA, Yang S, et al. Norepinephrine regulates hepatic innate immune system in leptin deficient mice with nonalcoholic steatohepatitis. Hepatology. 2004;40:434-441.
218. Guebre-Xabien M, Yang SQ, Lin HZ. Altered hepatic lymphocyte subpopulations in obesity related fatty livers. Hepatology. 1999;31:633-640.
219. Li Z, Diehl AM. Cytokines and inflammatory recruitment in NASH: experimental and human studies. In: Farrell GC, George J, Hall P, et al, eds. Fatty Liver Disease: NASH and Related Disorders. Oxford: Blackwell, 2005:123-131.
220. Vendeniale G, Grattagliano I, Caraceni P, et al. Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: effect of the nutritional status. Hepatology. 2001;33:808-815.
221. Sreekumar R, Gonzalez-Koch A, Maor-Kendlex Y, et al. Early identification of recipients with progressive histologic recurrence of hepatitis c after liver transplantation. Hepatology. 2000;32:1125-1130.
222. Abdelmalek MF, Angulo P, Torgensen RA, et al. Betaine, a promising new agent for patients with non-alcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol. 2001;96:2711-2717.
223. Mato JM, Alvarez L, Ortiz P, et al. S-Adenosylmethionine synthesis molecular mechanisms and clinical implications. Pharmacol Ther. 1997;73:265-280.
224. McClain CT, Hill DB, Song Z, et al. S-adenosylmethionine, cytokines, and liver disease. Alcohol. 2002;27:185-202.
225. Duce AM, Ortiz P, Cahrero M, et al. S-Adenosyl-L-methionine synthetase and phospholipid methyltransferase are inhibited in human cirrhosis. Hepatology. 1988;8:65-68.
226. Lu SC, Alvarez L, Huang ZZ, et al. Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation. Proc Natl Acad Sci USA. 2001;98:5560-5565.
227. Mato JM, Camara J, Fernandez de Paz J, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999;30:1081-1089.
228. Lieber CS. Role of S-adenosyl-L-methionine in the treatment of liver disease. J Hepatol. 1999;30:1115-1159.
229. Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med. 2000;108:9-13.